DURECT (NASDAQ:DRRX) Earns Neutral Rating from HC Wainwright

DURECT (NASDAQ:DRRX)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a report released on Thursday,Benzinga reports.

Separately, StockNews.com began coverage on DURECT in a research report on Thursday. They set a “sell” rating on the stock.

DURECT Price Performance

Shares of NASDAQ:DRRX traded down $0.00 during trading on Thursday, reaching $0.80. 17,892 shares of the company’s stock traded hands, compared to its average volume of 52,997. The stock has a market capitalization of $24.87 million, a P/E ratio of -1.31 and a beta of 0.91. DURECT has a 12 month low of $0.70 and a 12 month high of $1.88. The company has a 50 day moving average of $0.80 and a 200-day moving average of $1.01.

Institutional Trading of DURECT

Large investors have recently modified their holdings of the company. Jane Street Group LLC boosted its stake in DURECT by 266.0% during the 4th quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 28,486 shares during the period. Geode Capital Management LLC boosted its position in shares of DURECT by 4.8% during the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 14,658 shares during the period. Finally, Richmond Brothers Inc. boosted its position in shares of DURECT by 12.2% during the fourth quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock worth $961,000 after buying an additional 138,920 shares during the period. Institutional investors and hedge funds own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.